Sign in5 stories
Both offerings closed September 25, 2026, after underwriters fully exercised their over-allotment options, following topline VK2735 maintenance dosing data.
SEC filing (5)
Less frequent dosing after weekly induction preserved most weight loss, with tolerability similar to placebo, Viking said September 22, 2026.
SEC filing
Viking Therapeutics said its two subcutaneous VK2735 Phase 3 obesity trials are fully enrolled while it prepares to start an oral Phase 3 program and ended the quarter with $502 million in cash.
SEC filing